Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
Go back to Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease| ALDEYRA THERAPEUT (NASDAQ: ALDX) | Delayed: 2.27 -0.16 (6.58%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.43 | 52 Week High | $8.19 | |||
| Open | $2.41 | 52 Week Low | $3.39 | |||
| Day High | $2.53 | P/E | N/A | |||
| Day Low | $2.25 | EPS | $0.00 | |||
| Volume | 2,118,632 | |||||
